CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

. 2017 Dec 20 ; 7 (12) : 659. [epub] 20171220

Jazyk angličtina Země Spojené státy americké Médium electronic

Typ dokumentu dopisy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid29259173
E-zdroje Online Plný text
Odkazy

PubMed 29259173
PubMed Central PMC5802535
DOI 10.1038/s41408-017-0023-x
PII: 10.1038/s41408-017-0023-x
Knihovny.cz E-zdroje

Zobrazit více v PubMed

Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 2016;14:357–362. doi: 10.1016/j.csbj.2016.09.003. PubMed DOI PMC

Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer. 2016;63:1113–1115. doi: 10.1002/pbc.25953. PubMed DOI

Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295. doi: 10.1158/2159-8290.CD-15-1020. PubMed DOI PMC

Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–2410. doi: 10.1182/blood-2015-08-665547. PubMed DOI PMC

Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr. J. Hematol. Infect. Dis. 2014;6:e2014073. doi: 10.4084/mjhid.2014.073. PubMed DOI PMC

Kantarjian H, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 2017;376:836–847. doi: 10.1056/NEJMoa1609783. PubMed DOI PMC

Topp MS, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 2014;32:4134–4140. doi: 10.1200/JCO.2014.56.3247. PubMed DOI

Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet. Oncol. 2015;16:57–66. doi: 10.1016/S1470-2045(14)71170-2. PubMed DOI

von Stackelberg A, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 2016;34:4381–4389. doi: 10.1200/JCO.2016.67.3301. PubMed DOI

Shah NN, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr. Blood Cancer. 2015;62:964–969. doi: 10.1002/pbc.25410. PubMed DOI PMC

Barrena S, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia. 2005;19:1376–1383. doi: 10.1038/sj.leu.2403822. PubMed DOI

Braig F, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129:100–104. doi: 10.1182/blood-2016-05-718395. PubMed DOI

Slamova L, et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. Leukemia. 2014;28:609–620. doi: 10.1038/leu.2013.354. PubMed DOI

Nagel, I. et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy. Blood130, 2027–2031 (2017). PubMed PMC

Cherian, S. et al. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry B. Clin. Cytom. 2016; e-pub ahead of print 6 September 2016, 10.1002/cyto.b.21482. PubMed

Najít záznam

Citační ukazatele

Možnosti archivace